The primary drug used to treat the sexually transmitted infection could be scarce into next year, Pfizer warns.
Category: Drugs (Pharmaceuticals)
-
What to Know About Leqembi, the Alzheimer’s Drug Approved by the FDA
Medicare will cover much of the cost for patients in the early stages of the disease, but Leqembi has safety risks and can only modestly slow cognitive decline.
-
FDA Makes Alzheimer’s Drug Leqembi Widely Accessible
The F.D.A. gave full approval to the drug, but added a black-box warning about safety risks. Medicare said it would cover most of the high cost.
-
Retiree Medical Costs Expected to Stay Flat in 2023
An estimate puts the average cost over a 20-year retirement at about $157,000. That’s almost double the estimate in 2002.
-
How Vivek Ramaswamy Made the Fortune Fueling His Presidential Run
Mr. Ramaswamy calls himself a scientist from the biotech industry, but his vast fortune stems from two huge paydays that speak to hope and hype in the world of finance.
-
How the Shortage of a $15 Cancer Drug Is Upending Treatment
Older generic chemotherapy drugs remain scarce, forcing doctors to put a priority on the patients who have the best chance of survival.
-
What Is ‘Food Noise’? How Ozempic Quiets Obsessive Thinking About Food
For some, it’s a startling side effect.
-
The Business of Being Chris Christie
Mr. Christie left the governor’s office in New Jersey and set out to, as he put it, “make money.” He successfully traded on his political profile — and on his ties to the man he now wants to defeat.
-
New Obesity Drugs Come With a Side Effect of Shaming
Wegovy and other drugs expose a social tension between a quest to medicate illness and a stigmatizing belief that obese people lack sufficient willpower to lose weight.
-
Merck Sues Over Medicare Drug-Price Negotiation Law
The company is heavily reliant on a cancer drug that could be targeted by a program intended to lower drug prices.
-
An Appeals Court Gave the Sacklers Legal Immunity. Here’s What the Ruling Means.
In return for the shield, the billionaire owners of Purdue Pharma are committed to paying up to $6 billion to help compensate communities and individuals for the ravages of the opioid epidemic.